1-[4-(4-Methylpiperazin-1-yl)piperidin-1-yl]propan-1-one

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 哌啶类
• 英文名称: 1-[4-(4-Methylpiperazin-1-yl)piperidin-1-yl]propan-1-one
• 英文别名: 1-[4-(4-methylpiperazin-1-yl)piperidin-1-yl]propan-1-one
• 化学式: C₁₃H₂₅N₃O
• 分子量: 239.36
• InChiKey: WCDOLCHKFUGYMO-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  0.6
• 重原子数：
  17
• 可旋转键数：
  2
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.92
• 拓扑面积：
  26.8
• 氢给体数：
  0
• 氢受体数：
  3

文献信息

• JANUS KINASES INHIBITORS, COMPOSITIONS THEREOF AND USE THEREOF
  申请人：F. Hoffmann-La Roche AG

  公开号：EP3380474B1

  公开（公告）日：2019-08-21
• PYRAZOLOCHLOROPHENYL COMPOUNDS, COMPOSITIONS AND METHODS OF USE THEREOF
  申请人：F. Hoffmann-La Roche AG

  公开号：EP3596072B1

  公开（公告）日：2022-06-22
• PYRIMIDO-DIAZEPINONE KINASE SCAFFOLD COMPOUNDS AND METHODS OF TREATING DISORDERS
  申请人：Dana-Farber Cancer Institute, Inc.

  公开号：US20170260208A1

  公开（公告）日：2017-09-14

  The present invention relates to novel pyrimido-diazepinone compounds, methods of modulating protein kinases, including MPS1 (TTK), ERK5 (BMK1, MAPK7), polo kinase 1, 2, 3, or 4, Ack1, Ack2, Abl, DCAMKL1, ABL1, Abl mutants, DCAMKL2, ARK5, BRK, MKNK2, FGFR4, TNK1, PLK1, ULK2, PLK4, PRKD1, PRKD2, PRKD3, ROS1, RPS6KA6, TAOK1, TAOK3, TNK2, Bcr-Abl, GAK, cSrc, TPR-Met, Tie2, MET, FGFR3, Aurora, Axl, Bmx, BTK, c-kit, CHK2, Flt3, MST2, p70S6K, PDGFR, PKB, PKC, Raf, ROCK-H, Rsk1, SGK, TrkA, TrkB and TrkC, and the use of such compounds in the treatment of various diseases, disorders or conditions.
• [EN] JANUS KINASES INHIBITORS, COMPOSITIONS THEREOF AND USE THEREOF<br/>[FR] INHIBITEURS DES JANUS KINASES, LEURS COMPOSITIONS ET LEUR UTILISATION
  申请人：HOFFMANN LA ROCHE

  公开号：WO2017089390A1

  公开（公告）日：2017-06-01

  Compounds of Formula (00A) and salts thereof, wherein R1, R2 R3, R4 and n are defined herein, are useful as inhibitors of one or more Janus kinases. Also provided are pharmaceutical compositions that include a compound of Formula (00A) and a pharmaceutically acceptable carrier, adjuvant or vehicle, and methods of treating or lessening the severity of a disease or condition responsive to the inhibition of a Janus kinase activity in a patient. ( 00A)